---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-089004"
form_type: "8-K"
ticker: "VCNX"
cik: "0001205922"
company_name: "VACCINEX, INC."
filed_at: "2023-04-03T23:59:59+00:00"
generated_at: "2026-06-17T06:48:39.682704+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vaccinex raises ~$2.04M in private placement at $0.41/share; insider participation

## Summary
- Sold 4,975,608 shares at $0.41/share for gross proceeds of ~$2.04 million to three investors, including affiliates of CEO and chairman.
- Proceeds will fund development and clinical trials of lead drug candidate pepinemab in cancer and neurodegenerative disease, plus working capital.
- FCMI Parent Co., controlled by chairman Albert D. Friedberg, committed to purchase up to an additional $2.96 million of shares on or before May 15, 2023.
- Albert Friedberg covenanted to vote his shares in excess of 40% proportionately with other holders; registration rights granted to non-affiliated investor.
- Shares issued in private placement exempt from registration under Section 4(a)(2) of Securities Act and Rule 506 of Regulation D.

## SEC filing metadata
- accession: 0001193125-23-089004
- form_type: 8-K
- ticker: VCNX
- cik: 0001205922
- company_name: VACCINEX, INC.
- filed_at: 2023-04-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1205922/000119312523089004/0001193125-23-089004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1205922/000119312523089004/d462228d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-089004
- JSON: https://secwatch.observer/filing/0001193125-23-089004.json
- Plain text: https://secwatch.observer/filing/0001193125-23-089004.txt

## Key facts
- Material Agreements
  VACCINEX, INC. entered into Stock Purchase Agreement with Vaccinex (Rochester), L.L.C. and FCMI Parent Co. valued at aggregate gross proceeds of approximately $2.04 million (effective 2023-03-30).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Vaccinex (Rochester), L.L.C. and FCMI Parent Co.
  - Value: aggregate gross proceeds of approximately $2.04 million
  - Effective: 2023-03-30
  source text: On March 30, 2023, Vaccinex, Inc. (the “Company”) entered into a stock purchase agreement (the “Stock Purchase Agreement”) pursuant to which the Company agreed to issue and sell 4,975,608 shares of common stock of the Company (the “Shares”) at a purchase price of $0.41 per Share for aggregate gross proceeds of approximately $2.04 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1205922/000119312523089004/0001193125-23-089004-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.